Search Results

Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Cerevance will deliver a poster presentation at the upcoming Federation of European Neuroscience Societies (FENS) Forum 2024, taking place in Vienna, Austria, from June 25 – 29, 2024.

Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, announced that the peer-reviewed journal, ACS Medicinal Chemistry Letters, has published the manuscript titled “Discovery of CVN293, a Brain Permeable KCNK13 Inhibitor Suitable for Clinical Assessment”.

Cerevance today announced that company management will participate in the following investor conferences: Wells Fargo Virtual Private Biotech Symposium, May 6, 2024.

Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, will present an oral presentation at the upcoming International Association of Parkinsonism and Related Disorders XXIX World Congress on Parkinson’s Disease and Related Disorders, taking place in Lisbon, Portugal from May 19-22, 2024.

Spur Therapeutics, formerly Freeline Therapeutics, today announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system